FindTrial
Sign In

Hyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-525406-36-00
Enrollment
32
Registered
2026-09-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenocortical Carcinoma

Brief summary

The percentage of patients with local or peritoneal disease recurrence within 36 months after surgery.

Detailed description

Percentage of patients with major perioperative morbidity (grade > 2 according to the Clavien-Dindo classification of surgical complications)., Postoperative mortality rates at 30 and 90 days., Disease-specific survival up to 3 years after surgery.

Interventions

DRUGTHIOSULFATE
DRUGCISPLATIN
DRUGDOXORUBICIN

Sponsors

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The percentage of patients with local or peritoneal disease recurrence within 36 months after surgery.—

Secondary

MeasureTime frame
Percentage of patients with major perioperative morbidity (grade > 2 according to the Clavien-Dindo classification of surgical complications)., Postoperative mortality rates at 30 and 90 days., Disease-specific survival up to 3 years after surgery.—

Outcome results

None listed

Source: EU CTIS · Data processed: Sep 5, 2026